Access through your institution

通过您的机构访问

Buy or subscribe

购买或订阅

arising from M. Ferrell et al. Nature Medicine https://doi.org/10.1038/s41591-023-02793-8 (2024)Ferrell et al.1 recently reported associations between serum levels of the terminal niacin metabolites N1-methyl-2-pyridone-5-carboxamide (2PY) and N1-methyl-4-pyridone-3-carboxamide (4PY) with an increased 3-year incident risk of major adverse cardiovascular events.

源自M.Ferrell等人的《自然医学》https://doi.org/10.1038/s41591-023-02793-8（2024）Ferrell等[1]最近报道了末端烟酸代谢物N1-甲基-2-吡啶酮-5-甲酰胺（2PY）和N1-甲基-4-吡啶酮-3-甲酰胺（4PY）的血清水平与主要不良心血管事件的3年事件风险增加。

The association of 4PY with cardiovascular risk was linked to increased endothelial VCAM-1 expression and increased leukocyte adherence to the vascular endothelium as a potential causal mechanism. The study suggests that niacin supplementation may be harmful by increasing cardiovascular morbidity and mortality.

4PY与心血管风险的关联与内皮VCAM-1表达增加和白细胞对血管内皮的粘附增加有关，这是一种潜在的因果机制。该研究表明，补充烟酸可能会增加心血管疾病的发病率和死亡率。

Strikingly, the exact mechanism identified as a potential adverse outcome by Ferrell et al.1 has been noted to be suppressed with niacin supplementation2, arguing for a more complex interpretation of the findings. Here, we would like to briefly put the study of Ferrell et al.1 into the perspective of decades of clinical trial experience and pharmacovigilance with nicotinic acid (niacin) and nicotinamide, the two forms of vitamin B3..

引人注目的是，Ferrell等人1确定为潜在不良后果的确切机制已被烟酸补充剂2所抑制，认为对研究结果的解释更为复杂。在这里，我们想从几十年的临床试验经验和烟酸（烟酸）和烟酰胺（维生素B3的两种形式）的药物警戒的角度简要介绍费雷尔等人的研究。。

This is a preview of subscription content, access via your institution

这是订阅内容的预览，可通过您的机构访问

Access options

访问选项

Access through your institution

通过您的机构访问

Access through your institution

通过您的机构访问

Change institution

变革机构

Buy or subscribe

购买或订阅

Access Nature and 54 other Nature Portfolio journalsGet Nature+, our best-value online-access subscription24,99 € / 30 dayscancel any timeLearn moreSubscription info for Chinese customersWe have a dedicated website for our Chinese customers. Please go to naturechina.com to subscribe to this journal.Go to naturechina.comBuy this articlePurchase on SpringerLinkInstant access to full article PDFBuy nowPrices may be subject to local taxes which are calculated during checkout.

Access Nature和54篇其他Nature Portfolio journalsGet Nature+，我们最有价值的在线订阅24,99欧元/30天，随时为中国客户获取更多订阅信息我们为中国客户提供了一个专门的网站。请访问naturechina.com订阅本期刊。访问naturechina.comBuy本文在Springerlink上购买即时访问完整文章PDFBuy now价格可能需要缴纳结帐时计算的地方税。

Additional access options:

其他访问选项：

Log in

登录

Learn about institutional subscriptions

了解机构订阅

Read our FAQs

阅读我们的常见问题

Contact customer support

联系客户支持

ReferencesFerrell, M. et al. A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk. Nat. Med. 30, 424–434 (2024).Article

参考文献Ferrell，M。等人。烟酸的末端代谢物促进血管炎症并导致心血管疾病风险。《自然医学》30424-434（2024）。文章

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Wu, B. J. et al. Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids. Arterioscler. Thromb. Vasc. Biol. 30, 968–975 (2010).Article

Wu，B.J.等人的证据表明，烟酸抑制急性血管炎症并改善内皮功能障碍，而与血脂的变化无关。。血栓。Vasc。生物学杂志30968-975（2010）。文章

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Jenkins, D. J. A. et al. Supplemental vitamins and minerals for CVD prevention and treatment. J. Am. Coll. Cardiol. 71, 2570–2584 (2018).Article

Jenkins，D.J.A.等人。补充维生素和矿物质以预防和治疗心血管疾病。J、 美国科罗拉多州。心脏病。712570-2584（2018）。文章

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Superko, H. R., Zhao, X. Q., Hodis, H. N. & Guyton, J. R. Niacin and heart disease prevention: engraving its tombstone is a mistake. J. Clin. Lipidol. 11, 1309–1317 (2017).Article

Superko，H.R.，Zhao，X.Q.，Hodis，H.N。和Guyton，J.R。烟酸和心脏病预防：雕刻墓碑是一个错误。J、 临床。利皮多尔。11309-1317（2017）。文章

PubMed

PubMed

Google Scholar

谷歌学者

Canner, P. L. et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J. Am. Coll. Cardiol. 8, 1245–1255 (1986).Article

Canner，P.L.等人，《冠状动脉药物项目患者的15年死亡率：烟酸的长期益处》。J、 美国科罗拉多州。心脏病。81245-1255（1986）。文章

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Capuzzi, D. M. et al. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am. J. Cardiol. 82, 74U–81U (1998).Article

Capuzzi，D.M.等人。缓释烟酸（Niaspan）的有效性和安全性：一项长期研究。美国心脏病杂志。8274U–81U（1998年）。文章

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Bruckert, E., Labreuche, J. & Amarenco, P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 210, 353–361 (2010).Article

Bruckert，E.，Labreuche，J。＆Amarenco，P。单独或联合使用烟酸对心血管事件和动脉粥样硬化影响的荟萃分析。动脉粥样硬化210353-361（2010）。文章

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Lavigne, P. M. & Karas, R. H. The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression. J. Am. Coll. Cardiol. 61, 440–446 (2013).Article

。J、 美国科罗拉多州。心脏病。61440-446（2013）。文章

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Sahebkar, A. Effect of niacin on endothelial function: a systematic review and meta-analysis of randomized controlled trials. Vasc. Med. 19, 54–66 (2014).Article

Sahebkar，A。烟酸对内皮功能的影响：随机对照试验的系统评价和荟萃分析。Vasc。医学杂志19,54-66（2014）。文章

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

D’Andrea, E., Hey, S. P., Ramirez, C. L. & Kesselheim, A. S. Assessment of the role of niacin in managing cardiovascular disease outcomes: a systematic review and meta-analysis. JAMA Netw. Open 2, e192224 (2019).Article

D'Andrea，E.，Hey，S.P.，Ramirez，C.L。和Kesselheim，A.S。评估烟酸在管理心血管疾病结果中的作用：系统评价和荟萃分析。JAMA网络。开放2，e192224（2019）。文章

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

EFSA NDA Panel. Scientific Opinion on Dietary Reference Values for niacin (EFSA Panel on Dietetic Products, Nutrition and Allergies). EFSA J. 12, 3759 (2014).Article

欧洲食品安全局NDA专家组。烟酸膳食参考值的科学意见（欧洲食品安全局饮食产品、营养和过敏专家组）。EFSA J.123759（2014）。文章

Google Scholar

谷歌学者

Knip, M. et al. Safety of high-dose nicotinamide: a review. Diabetologia 43, 1337–1345 (2000).Article

Knip，M.等人。大剂量烟酰胺的安全性：综述。糖尿病学431337-1345（2000）。文章

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Abdellatif, M. et al. Nicotinamide for the treatment of heart failure with preserved ejection fraction. Sci. Transl. Med. 13, eabd7064 (2021).Article

Abdellatif，M。等人。烟酰胺治疗射血分数保留的心力衰竭。科学。翻译。医学杂志13，eabd7064（2021）。文章

CAS

中科院

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Hashimoto, T. et al. ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature 487, 477–481 (2012).Article

桥本，T。等人。ACE2将氨基酸营养不良与微生物生态学和肠道炎症联系起来。自然487477-481（2012）。文章

CAS

中科院

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Sudar-Milovanovic, E., Gluvic, Z., Obradovic, M., Zaric, B. & Isenovic, E. R. Tryptophan metabolism in atherosclerosis and diabetes. Curr. Med. Chem. 29, 99–113 (2022).Article

Sudar Milovanovic，E.，Gluvic，Z.，Obradovic，M.，Zaric，B。＆Isenovic，E.R。动脉粥样硬化和糖尿病中的色氨酸代谢。货币。医学化学。29，99-113（2022）。文章

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Download referencesAuthor informationAuthors and AffiliationsDepartment of Internal Medicine I, University Hospital Schleswig-Holstein, Kiel, GermanyStefan Schreiber & Matthias LaudesInstitute of Clinical Molecular Biology, Kiel University and University Hospital Schleswig-Holstein, Kiel, GermanyStefan Schreiber, Georg H.

下载参考文献作者信息作者和附属机构德国基尔施莱斯维格-荷尔斯泰因大学医院内科I，基尔施莱斯维格-荷尔斯泰因大学临床分子生物学研究所。

Waetzig & Philip RosenstielCONARIS Research Institute AG, Kiel, GermanyGeorg H. WaetzigInstitute of Diabetes and Clinical Metabolism Research, Kiel University and University Hospital Schleswig-Holstein, Kiel, GermanyMatthias LaudesAuthorsStefan SchreiberView author publicationsYou can also search for this author in.

Waetzig＆Philip RosenstielCONARIS Research Institute AG，基尔，GermanyGeorg H.Waetzig糖尿病与临床代谢研究所，基尔大学和石勒苏益格-荷尔斯坦大学医院，基尔，GermanyMatthias LaudesAuthorsStefan SchreiberView作者出版物您也可以在中搜索这位作者。

PubMed Google ScholarGeorg H. WaetzigView author publicationsYou can also search for this author in

PubMed Google ScholarGeorg H.WaetzigView作者出版物您也可以在

PubMed Google ScholarMatthias LaudesView author publicationsYou can also search for this author in

PubMed Google ScholarMatthias LaudesView作者出版物您也可以在

PubMed Google ScholarPhilip RosenstielView author publicationsYou can also search for this author in

PubMed Google ScholarPhilip RosenstielView作者出版物您也可以在

PubMed Google ScholarContributionsS.S., G.H.W., M.L. and P.R. contributed to drafting and reviewing the paper.Corresponding authorCorrespondence to

PubMed谷歌学术贡献。S、 ，G.H.W.，M.L.和P.R.为论文的起草和审查做出了贡献。对应作者对应

Stefan Schreiber.Ethics declarations

斯特凡·施赖伯。道德宣言

Competing interests

相互竞争的利益

S.S. reports indirect stock ownership in Gerion Biotech as well as consulting and personal fees from AbbVie, Allergosan, Amgen, Arena, BMS, Biogen, Celltrion, Celgene, Falk, Ferring, Fresenius, Galapagos/Gilead, HIKMA, I-Mab, Janssen, Lilly, Morphic, MSD, Mylan, Pfizer, Prometheus, Protagonist, Provention Bio, Sandoz/Hexal, Takeda and Theravance.

S、 美国报告了Gerion Biotech的间接股权以及来自AbbVie、Allergosan、Amgen、Arena、BMS、Biogen、Celltrion、Celgene、Falk、Ferring、Fresenius、Galapagos/Gilead、HIKMA、I-Mab、Janssen、Lilly、Morphic、MSD、Mylan、Pfizer、Prometheus、Protagent、Provention Bio、Sandoz/Hexal、Takeda和Theravance的咨询和个人费用。

G.H.W. is in part-time employment by CONARIS Research Institute AG (Kiel, Germany). M.L. reports lecture fees from Amarin, AstraZeneca, Boehringer Ingelheim, Chiesi, HRA Pharma, Lilly, Novo Nordisk, Roche and Sanofi. P.R. reports stock ownership in Gerion Biotech and consulting fees from Takeda..

G、 H.W.在CONARIS Research Institute AG（德国基尔）兼职。M、 L.报告了阿玛林、阿斯利康、勃林格殷格翰、基耶西、HRA制药、礼来、诺和诺德、罗氏和赛诺菲的讲座费用。P、 R.报告了Gerion Biotech的股权和武田的咨询费。。

Additional informationPublisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.Rights and permissionsReprints and permissionsAbout this articleCite this articleSchreiber, S., Waetzig, G.H., Laudes, M. et al. Cardiovascular safety of vitamin B3 administration..

Additional informationPublisher的注释Springer Nature在已发布的地图和机构隶属关系中的管辖权主张方面保持中立。权利和许可打印和许可本文引用本文Schreiber，S.，Waetzig，G.H.，Laudes，M。等人。维生素B3给药的心血管安全性。。

Nat Med (2024). https://doi.org/10.1038/s41591-024-03219-9Download citationReceived: 15 March 2024Accepted: 30 July 2024Published: 05 September 2024DOI: https://doi.org/10.1038/s41591-024-03219-9Share this articleAnyone you share the following link with will be able to read this content:Get shareable linkSorry, a shareable link is not currently available for this article.Copy to clipboard.

Nat Med（2024）。https://doi.org/10.1038/s41591-024-03219-9Download引文接收日期：2024年3月15日接受日期：2024年7月30日发布日期：2024年9月5日OI：https://doi.org/10.1038/s41591-024-03219-9Share本文与您共享以下链接的任何人都可以阅读此内容：获取可共享链接对不起，本文目前没有可共享的链接。复制到剪贴板。

Provided by the Springer Nature SharedIt content-sharing initiative

由Springer Nature SharedIt内容共享计划提供